Patent
US 9,402,910INTERNALLY FUNCTIONALIZED GRAPHENE SUBSTRATES
Jeffrey Alan McKinney
US
Copyright © 2026 Matter42. All rights reserved.
Patent
Atlas literature
Patent
US 9,402,910Patent drawings and their descriptions. Click a drawing to enlarge it.
FIG. 1 is an illustration of a graphene substrate (100) having non-edge regions (110) and edge regions (120).
FIG. 2 is an illustration of a graphene substrate (200) having holes (210) where there is no graphene, edge regions (220) and non-edge regions (230).
FIG. 3 is an illustration of a portion of a graphene substrate (300) having non-edge regions (310) and epoxy groups (320) within the non-edge regions.
FIG. 4 is an illustration of a portion of a graphene substrate (400) having non-edge regions (410) and hydroxyl groups (420) within the non-edge regions.
FIG. 5 is an illustration of a graphene substrate (500) having non-edge regions (510) and edge regions (520), and where the non-edge regions are functionalized …
FIG. 6 is an illustration of a graphene substrate (600) having edge regions (620) and non- edge regions (630), as well as holes (610) where there is no …
FIG. 7 is an illustration of three ribbons (700) of graphene substrates that have edge regions (710), non-edge regions (720), and where the non-edge regions …
FIG. 8 is an illustration of system (800) of interconnected graphene substrates (810), where the graphene substrates have edge regions (830) and non-edge …
FIG. 9 is an illustration of the functionalization of epoxy groups (920) on non-edge regions (910) of a portion of a graphene substrate (900) through reaction …
FIG. 10 is an illustration of the functionalization of hydroxyl groups (1020) on non-edge regions (1010) of a portion of a graphene substrate (1000) through …
FIG. 11 is an illustration of a portion of a graphene substrate (1100) functionalized on a non-edge region (1110) with an amine including a pyrene moiety …
FIG. 12 is an illustration of a portion of a graphene substrate (1200) f u nctionalized on a non- edge region (1210) with an amine including an ammonium ion …
FIG. 13 is an illustration of a portion of a graphene substrate (1300) functionalized on a non-edge region (1310) with an amine including a biotin moiety …
FIG. 14 is an illustration of a portion of a graphene substrate (1400) functionalized on a non-edge region (1410) with an amine including a thiol moiety (1440) …
FIG. 15 is an illustration of a portion of a graphene substrate (1500) functionalized on a non-edge region (1510) with an amine including an amino triacetic …
FIG. 16 is an illustration of a portion of a graphene substrate (1600) functionalized on a non-edge region (1610) with an amine including an amino triacetic …
FIG. 17 is an illustration of a portion of a graphene substrate (1700) functionalized on a non-edge region (1710) through non-covalent association of a …
FIG. 18 is an illustration of a portion of a graphene substrate (1800) functionalized on a non-edge region (1810) through non-covalent association of an …
FIG. 19 is an illustration of a portion of a graphene substrate (1900) functionalized on a non-edge region (1910) through non-covalent association of a …
FIG. 20 is an illustration of a portion of a graphene substrate (2000) functionalized on a non-edge region (2010) through non-covalent association of a …
FIG. 21 is an illustration of a molecule (2140) bound to a graphene substrate (2100) through a bond (2110) where a binding site (2150) on the molecule is …
FIG. 22 is an illustration of a side view of a graphene substrate (2200) adhered to a supporting substrate (2210).
Claims define the patent's legal scope. Independent claims stand alone; dependent claims (nested) narrow them. Click a claim to expand its dependents.
A graphene substrate, wherein the substrate comprises edge and non-edge regions, and wherein organic or inorganic molecules are bound to a nucleophilic moiety covalently linked to a carbon molecule in the non-edge regions of the substrate, and wherein the organic or inorganic molecules are present on the non-edge regions at a population greater than about one molecule per 30,000 nm 2
The graphene substrate according to claim 1, wherein organic molecules are present on the substrate, and wherein the organic molecules are selected from a group consisting of: antibodies; antibody fragments; aptamers; large molecule therapeutics; oligonucleotides; oligopeptides; oligosaccharides, proteins and small molecule therapeutics.
A method of functionalizing a graphene substrate, wherein the method comprises the steps of: a) obtaining a graphene substrate that has edge regions and non-edge regions, wherein the nonedge regions comprise epoxy moieties; b) reacting the epoxy moieties with a Nu-M, wherein Nu is a nucleophilic moiety and M is an attached organic or inorganic moiety, thereby functionalizing the graphene substrate. withdrawn
The method according to claim 14, wherein Nu is NH 2, and wherein M is an attached organic moiety, and wherein the organic moiety is selected from a group of organic moieties consisting of: an antibody; a linking group attached to an antibody; an antibody fragment; a linking group attached to an antibody fragment; a linking group attached to an aptamer; a protein; a linking group attached to a protein; an oligopeptide; a linking group attached to an oligopeptide; a linking group attached to an oligosaccharide; a large molecule therapeutic; a linking group attached to a large molecule therapeutic; a small molecule therapeutic; a linking group attached to a small molecule therapeutic. withdrawn
A method of functionalizing a graphene substrate, wherein the method comprises the steps of. a) obtaining a graphene substrate that has edge regions and non-edge regions, wherein the nonedge regions comprise hydroxy moieties; Attorney Docket No: Client Ref: US SN: 14/120,928 b) reacting the hydroxyl moieties with a E-M, wherein E is an electrophilic moiety and M is an attached organic or inorganic moiety, thereby functionalizing the graphene substrate. withdrawn
The method according to claim 19, wherein EM is OCN-Protein, wherein the N atom is part of the protein, and wherein the protein is selected from a group of proteins consisting of. Insulin; Pramlintide; Growth hormone; Mecasermin; Factor VIII; Factor IX; Antithrombin III; Protein C; B-Gluco-cerebrosidase; Alglucosidase- a; Laronidase; Idursulphase; Galsulphase; Agalsidase- 0; A- 1 -Proteinase inhibitor; Lactase; Lipase; Amylase; Protease; Adenosine deaminase; Human albumin; Erythropoietin; Darbepoetin- a; Filgrastim; Sargramostim; Oprelvekin; Human follicle-stimulating hormone; Human chorionic gonadotropin; Lutropin- a; Type I a -interferon; Interferon- a 2a; Interferon- a 2b; Interferon- a n3; Interferon- l a; Interferon- l b; Interferon- yl b; Aldesleukin; Alteplase; Reteplase; Tenecteplase; Urokinase; Factor VI I a; Drotrecogin- a; Salmon calcitonin; Teriparatide; Exenatide; Octreotide; Dibotermin- a; Recombinant human bone morphogenic protein 7; Histrelin; Palifermin; Becaplermin; Trypsin; Nesiritide; Botulinum toxin type A; Botulinum toxin type B; Collagenase; Human deoxy-ribonuclease I; Hyaluronidase; Papain; L-Asparaginase; Rasburicase; Lepirudin; Bivalirudin; Streptokinase; Anistreplase; Bevacizumab; Cetuximab; Panitumumab; Alemtuzumab; Rituximab; Trastuzumab; Abtacept; Anakinra; Adalimumab; Etanercept; Infliximab; Alefacept; Efalizumab; Natalizumab; Eculizumab; Antithymocyte globulin; Basiliximab; Daclizumab; Muromonab-CD3; Omalizumab; Palivizumab; Enfuvirtide; Abciximab; Pegvisomant; Crotalidae polyvalent immune Fab; Digoxin immune serum Fab; Ranibizumab; Denileukin diftitox; Ibritumomab tiuxetan; Gemtuzumab ozogamicin; Tositumomab; DNA polymerase. withdrawn
A method of functionalizing a graphene substrate, wherein the method comprises the steps of: withdrawn
The method according to claim 23, wherein the molecule is a protein, and wherein the protein is selected from a group of proteins consisting of: Insulin; Pramlintide; Growth hormone; Mecasermin; Factor VIII; Factor IX; Antithrombin III; Protein C; B-Gluco- cerebrosidase; Alglucosidase- a; Laronidase; Idursulphase; Galsulphase; Agalsidase- 0; A- 1- Proteinase inhibitor; Lactase; Lipase; Amylase; Protease; Adenosine deaminase; Human albumin; Erythropoietin; Darbepoetin- a; Filgrastim; Sargramostim; Oprelvekin; Human follicle- stimulating hormone; Human chorionic gonadotropin; Lutropin- a; Type I a-i nterferon; Attorney Docket No: Client Ref: US SN: 14/120,928 I nterferon- a 2a; I nterferon- a 2b; I nterferon- a n3; I nterferon- l a; I nterferon- l b; I nterferon- ylb; Aldesleukin; Alteplase; Reteplase; Tenecteplase; Urokinase; Factor VI I a; Drotrecogin- a; Salmon calcitonin; Teriparatide; Exenatide; Octreotide; Dibotermin- a; Recombinant human bone morphogenic protein 7; Histrelin; Palifermin; Becaplermin; Trypsin; Nesiritide; Botulinum toxin type A; Botulinum toxin type B; Collagenase; Human deoxy-ribonuclease I; Hyaluronidase; Papain; L-Asparaginase; Rasburicase; Lepirudin; Bivalirudin; Streptokinase; Anistreplase; Bevacizumab; Cetuximab; Panitumumab; Alemtuzumab; Rituximab; Trastuzumab; Abtacept; Anakinra; Adalimumab; Etanercept; Infliximab; Alefacept; Efalizumab; Natalizumab; Eculizumab; Antithymocyte globulin; Basiliximab; Daclizumab; Muromonab-CD3; Omalizumab; Palivizumab; Enfuvirtide; Abciximab; Pegvisomant; Crotalidae polyvalent immune Fab; Digoxin immune serum Fab; Ranibizumab; Denileukin diftitox; Ibritumomab tiuxetan; Gemtuzumab ozogamicin; Tositumomab; DNA polymerase. withdrawn
Layer stacks claimed or described, ordered top of device to substrate.
internally functionalized graphene substrate
Materials described outside the worked examples.
graphene substrate
nucleophilic moiety covalently linked to carbon
organic molecules (antibodies, antibody fragments, aptamers, large molecule therapeutics, oligonucleotides, oligopeptides, oligosaccharides, proteins, small molecule therapeutics)
Additional fabrication and treatment steps described in the patent.
Performance values and ranges asserted in the specification or claims.
| Property | Value | Material |
|---|---|---|
Thickness | 20–180 nm | — |
Thickness | ≤ 50 nm |
Related documents with shared materials, methods, properties, or citations.
Patent
Atlas literature
Patent
US 9,402,910Patent drawings and their descriptions. Click a drawing to enlarge it.
FIG. 1 is an illustration of a graphene substrate (100) having non-edge regions (110) and edge regions (120).
FIG. 2 is an illustration of a graphene substrate (200) having holes (210) where there is no graphene, edge regions (220) and non-edge regions (230).
FIG. 3 is an illustration of a portion of a graphene substrate (300) having non-edge regions (310) and epoxy groups (320) within the non-edge regions.
FIG. 4 is an illustration of a portion of a graphene substrate (400) having non-edge regions (410) and hydroxyl groups (420) within the non-edge regions.
FIG. 5 is an illustration of a graphene substrate (500) having non-edge regions (510) and edge regions (520), and where the non-edge regions are functionalized …
FIG. 6 is an illustration of a graphene substrate (600) having edge regions (620) and non- edge regions (630), as well as holes (610) where there is no …
FIG. 7 is an illustration of three ribbons (700) of graphene substrates that have edge regions (710), non-edge regions (720), and where the non-edge regions …
FIG. 8 is an illustration of system (800) of interconnected graphene substrates (810), where the graphene substrates have edge regions (830) and non-edge …
FIG. 9 is an illustration of the functionalization of epoxy groups (920) on non-edge regions (910) of a portion of a graphene substrate (900) through reaction …
FIG. 10 is an illustration of the functionalization of hydroxyl groups (1020) on non-edge regions (1010) of a portion of a graphene substrate (1000) through …
FIG. 11 is an illustration of a portion of a graphene substrate (1100) functionalized on a non-edge region (1110) with an amine including a pyrene moiety …
FIG. 12 is an illustration of a portion of a graphene substrate (1200) f u nctionalized on a non- edge region (1210) with an amine including an ammonium ion …
FIG. 13 is an illustration of a portion of a graphene substrate (1300) functionalized on a non-edge region (1310) with an amine including a biotin moiety …
FIG. 14 is an illustration of a portion of a graphene substrate (1400) functionalized on a non-edge region (1410) with an amine including a thiol moiety (1440) …
FIG. 15 is an illustration of a portion of a graphene substrate (1500) functionalized on a non-edge region (1510) with an amine including an amino triacetic …
FIG. 16 is an illustration of a portion of a graphene substrate (1600) functionalized on a non-edge region (1610) with an amine including an amino triacetic …
FIG. 17 is an illustration of a portion of a graphene substrate (1700) functionalized on a non-edge region (1710) through non-covalent association of a …
FIG. 18 is an illustration of a portion of a graphene substrate (1800) functionalized on a non-edge region (1810) through non-covalent association of an …
FIG. 19 is an illustration of a portion of a graphene substrate (1900) functionalized on a non-edge region (1910) through non-covalent association of a …
FIG. 20 is an illustration of a portion of a graphene substrate (2000) functionalized on a non-edge region (2010) through non-covalent association of a …
FIG. 21 is an illustration of a molecule (2140) bound to a graphene substrate (2100) through a bond (2110) where a binding site (2150) on the molecule is …
FIG. 22 is an illustration of a side view of a graphene substrate (2200) adhered to a supporting substrate (2210).
Claims define the patent's legal scope. Independent claims stand alone; dependent claims (nested) narrow them. Click a claim to expand its dependents.
A graphene substrate, wherein the substrate comprises edge and non-edge regions, and wherein organic or inorganic molecules are bound to a nucleophilic moiety covalently linked to a carbon molecule in the non-edge regions of the substrate, and wherein the organic or inorganic molecules are present on the non-edge regions at a population greater than about one molecule per 30,000 nm 2
The graphene substrate according to claim 1, wherein organic molecules are present on the substrate, and wherein the organic molecules are selected from a group consisting of: antibodies; antibody fragments; aptamers; large molecule therapeutics; oligonucleotides; oligopeptides; oligosaccharides, proteins and small molecule therapeutics.
A method of functionalizing a graphene substrate, wherein the method comprises the steps of: a) obtaining a graphene substrate that has edge regions and non-edge regions, wherein the nonedge regions comprise epoxy moieties; b) reacting the epoxy moieties with a Nu-M, wherein Nu is a nucleophilic moiety and M is an attached organic or inorganic moiety, thereby functionalizing the graphene substrate. withdrawn
The method according to claim 14, wherein Nu is NH 2, and wherein M is an attached organic moiety, and wherein the organic moiety is selected from a group of organic moieties consisting of: an antibody; a linking group attached to an antibody; an antibody fragment; a linking group attached to an antibody fragment; a linking group attached to an aptamer; a protein; a linking group attached to a protein; an oligopeptide; a linking group attached to an oligopeptide; a linking group attached to an oligosaccharide; a large molecule therapeutic; a linking group attached to a large molecule therapeutic; a small molecule therapeutic; a linking group attached to a small molecule therapeutic. withdrawn
A method of functionalizing a graphene substrate, wherein the method comprises the steps of. a) obtaining a graphene substrate that has edge regions and non-edge regions, wherein the nonedge regions comprise hydroxy moieties; Attorney Docket No: Client Ref: US SN: 14/120,928 b) reacting the hydroxyl moieties with a E-M, wherein E is an electrophilic moiety and M is an attached organic or inorganic moiety, thereby functionalizing the graphene substrate. withdrawn
The method according to claim 19, wherein EM is OCN-Protein, wherein the N atom is part of the protein, and wherein the protein is selected from a group of proteins consisting of. Insulin; Pramlintide; Growth hormone; Mecasermin; Factor VIII; Factor IX; Antithrombin III; Protein C; B-Gluco-cerebrosidase; Alglucosidase- a; Laronidase; Idursulphase; Galsulphase; Agalsidase- 0; A- 1 -Proteinase inhibitor; Lactase; Lipase; Amylase; Protease; Adenosine deaminase; Human albumin; Erythropoietin; Darbepoetin- a; Filgrastim; Sargramostim; Oprelvekin; Human follicle-stimulating hormone; Human chorionic gonadotropin; Lutropin- a; Type I a -interferon; Interferon- a 2a; Interferon- a 2b; Interferon- a n3; Interferon- l a; Interferon- l b; Interferon- yl b; Aldesleukin; Alteplase; Reteplase; Tenecteplase; Urokinase; Factor VI I a; Drotrecogin- a; Salmon calcitonin; Teriparatide; Exenatide; Octreotide; Dibotermin- a; Recombinant human bone morphogenic protein 7; Histrelin; Palifermin; Becaplermin; Trypsin; Nesiritide; Botulinum toxin type A; Botulinum toxin type B; Collagenase; Human deoxy-ribonuclease I; Hyaluronidase; Papain; L-Asparaginase; Rasburicase; Lepirudin; Bivalirudin; Streptokinase; Anistreplase; Bevacizumab; Cetuximab; Panitumumab; Alemtuzumab; Rituximab; Trastuzumab; Abtacept; Anakinra; Adalimumab; Etanercept; Infliximab; Alefacept; Efalizumab; Natalizumab; Eculizumab; Antithymocyte globulin; Basiliximab; Daclizumab; Muromonab-CD3; Omalizumab; Palivizumab; Enfuvirtide; Abciximab; Pegvisomant; Crotalidae polyvalent immune Fab; Digoxin immune serum Fab; Ranibizumab; Denileukin diftitox; Ibritumomab tiuxetan; Gemtuzumab ozogamicin; Tositumomab; DNA polymerase. withdrawn
A method of functionalizing a graphene substrate, wherein the method comprises the steps of: withdrawn
The method according to claim 23, wherein the molecule is a protein, and wherein the protein is selected from a group of proteins consisting of: Insulin; Pramlintide; Growth hormone; Mecasermin; Factor VIII; Factor IX; Antithrombin III; Protein C; B-Gluco- cerebrosidase; Alglucosidase- a; Laronidase; Idursulphase; Galsulphase; Agalsidase- 0; A- 1- Proteinase inhibitor; Lactase; Lipase; Amylase; Protease; Adenosine deaminase; Human albumin; Erythropoietin; Darbepoetin- a; Filgrastim; Sargramostim; Oprelvekin; Human follicle- stimulating hormone; Human chorionic gonadotropin; Lutropin- a; Type I a-i nterferon; Attorney Docket No: Client Ref: US SN: 14/120,928 I nterferon- a 2a; I nterferon- a 2b; I nterferon- a n3; I nterferon- l a; I nterferon- l b; I nterferon- ylb; Aldesleukin; Alteplase; Reteplase; Tenecteplase; Urokinase; Factor VI I a; Drotrecogin- a; Salmon calcitonin; Teriparatide; Exenatide; Octreotide; Dibotermin- a; Recombinant human bone morphogenic protein 7; Histrelin; Palifermin; Becaplermin; Trypsin; Nesiritide; Botulinum toxin type A; Botulinum toxin type B; Collagenase; Human deoxy-ribonuclease I; Hyaluronidase; Papain; L-Asparaginase; Rasburicase; Lepirudin; Bivalirudin; Streptokinase; Anistreplase; Bevacizumab; Cetuximab; Panitumumab; Alemtuzumab; Rituximab; Trastuzumab; Abtacept; Anakinra; Adalimumab; Etanercept; Infliximab; Alefacept; Efalizumab; Natalizumab; Eculizumab; Antithymocyte globulin; Basiliximab; Daclizumab; Muromonab-CD3; Omalizumab; Palivizumab; Enfuvirtide; Abciximab; Pegvisomant; Crotalidae polyvalent immune Fab; Digoxin immune serum Fab; Ranibizumab; Denileukin diftitox; Ibritumomab tiuxetan; Gemtuzumab ozogamicin; Tositumomab; DNA polymerase. withdrawn
Layer stacks claimed or described, ordered top of device to substrate.
internally functionalized graphene substrate
Materials described outside the worked examples.
graphene substrate
nucleophilic moiety covalently linked to carbon
organic molecules (antibodies, antibody fragments, aptamers, large molecule therapeutics, oligonucleotides, oligopeptides, oligosaccharides, proteins, small molecule therapeutics)
Additional fabrication and treatment steps described in the patent.
Performance values and ranges asserted in the specification or claims.
| Property | Value | Material |
|---|---|---|
Thickness | 20–180 nm | — |
Thickness | ≤ 50 nm |
Related documents with shared materials, methods, properties, or citations.
Patent
Atlas literature
Patent
US 9,402,910Patent drawings and their descriptions. Click a drawing to enlarge it.
FIG. 1 is an illustration of a graphene substrate (100) having non-edge regions (110) and edge regions (120).
FIG. 2 is an illustration of a graphene substrate (200) having holes (210) where there is no graphene, edge regions (220) and non-edge regions (230).
FIG. 3 is an illustration of a portion of a graphene substrate (300) having non-edge regions (310) and epoxy groups (320) within the non-edge regions.
FIG. 4 is an illustration of a portion of a graphene substrate (400) having non-edge regions (410) and hydroxyl groups (420) within the non-edge regions.
FIG. 5 is an illustration of a graphene substrate (500) having non-edge regions (510) and edge regions (520), and where the non-edge regions are functionalized …
FIG. 6 is an illustration of a graphene substrate (600) having edge regions (620) and non- edge regions (630), as well as holes (610) where there is no …
FIG. 7 is an illustration of three ribbons (700) of graphene substrates that have edge regions (710), non-edge regions (720), and where the non-edge regions …
FIG. 8 is an illustration of system (800) of interconnected graphene substrates (810), where the graphene substrates have edge regions (830) and non-edge …
FIG. 9 is an illustration of the functionalization of epoxy groups (920) on non-edge regions (910) of a portion of a graphene substrate (900) through reaction …
FIG. 10 is an illustration of the functionalization of hydroxyl groups (1020) on non-edge regions (1010) of a portion of a graphene substrate (1000) through …
FIG. 11 is an illustration of a portion of a graphene substrate (1100) functionalized on a non-edge region (1110) with an amine including a pyrene moiety …
FIG. 12 is an illustration of a portion of a graphene substrate (1200) f u nctionalized on a non- edge region (1210) with an amine including an ammonium ion …
FIG. 13 is an illustration of a portion of a graphene substrate (1300) functionalized on a non-edge region (1310) with an amine including a biotin moiety …
FIG. 14 is an illustration of a portion of a graphene substrate (1400) functionalized on a non-edge region (1410) with an amine including a thiol moiety (1440) …
FIG. 15 is an illustration of a portion of a graphene substrate (1500) functionalized on a non-edge region (1510) with an amine including an amino triacetic …
FIG. 16 is an illustration of a portion of a graphene substrate (1600) functionalized on a non-edge region (1610) with an amine including an amino triacetic …
FIG. 17 is an illustration of a portion of a graphene substrate (1700) functionalized on a non-edge region (1710) through non-covalent association of a …
FIG. 18 is an illustration of a portion of a graphene substrate (1800) functionalized on a non-edge region (1810) through non-covalent association of an …
FIG. 19 is an illustration of a portion of a graphene substrate (1900) functionalized on a non-edge region (1910) through non-covalent association of a …
FIG. 20 is an illustration of a portion of a graphene substrate (2000) functionalized on a non-edge region (2010) through non-covalent association of a …
FIG. 21 is an illustration of a molecule (2140) bound to a graphene substrate (2100) through a bond (2110) where a binding site (2150) on the molecule is …
FIG. 22 is an illustration of a side view of a graphene substrate (2200) adhered to a supporting substrate (2210).
Claims define the patent's legal scope. Independent claims stand alone; dependent claims (nested) narrow them. Click a claim to expand its dependents.
A graphene substrate, wherein the substrate comprises edge and non-edge regions, and wherein organic or inorganic molecules are bound to a nucleophilic moiety covalently linked to a carbon molecule in the non-edge regions of the substrate, and wherein the organic or inorganic molecules are present on the non-edge regions at a population greater than about one molecule per 30,000 nm 2
The graphene substrate according to claim 1, wherein organic molecules are present on the substrate, and wherein the organic molecules are selected from a group consisting of: antibodies; antibody fragments; aptamers; large molecule therapeutics; oligonucleotides; oligopeptides; oligosaccharides, proteins and small molecule therapeutics.
A method of functionalizing a graphene substrate, wherein the method comprises the steps of: a) obtaining a graphene substrate that has edge regions and non-edge regions, wherein the nonedge regions comprise epoxy moieties; b) reacting the epoxy moieties with a Nu-M, wherein Nu is a nucleophilic moiety and M is an attached organic or inorganic moiety, thereby functionalizing the graphene substrate. withdrawn
The method according to claim 14, wherein Nu is NH 2, and wherein M is an attached organic moiety, and wherein the organic moiety is selected from a group of organic moieties consisting of: an antibody; a linking group attached to an antibody; an antibody fragment; a linking group attached to an antibody fragment; a linking group attached to an aptamer; a protein; a linking group attached to a protein; an oligopeptide; a linking group attached to an oligopeptide; a linking group attached to an oligosaccharide; a large molecule therapeutic; a linking group attached to a large molecule therapeutic; a small molecule therapeutic; a linking group attached to a small molecule therapeutic. withdrawn
A method of functionalizing a graphene substrate, wherein the method comprises the steps of. a) obtaining a graphene substrate that has edge regions and non-edge regions, wherein the nonedge regions comprise hydroxy moieties; Attorney Docket No: Client Ref: US SN: 14/120,928 b) reacting the hydroxyl moieties with a E-M, wherein E is an electrophilic moiety and M is an attached organic or inorganic moiety, thereby functionalizing the graphene substrate. withdrawn
The method according to claim 19, wherein EM is OCN-Protein, wherein the N atom is part of the protein, and wherein the protein is selected from a group of proteins consisting of. Insulin; Pramlintide; Growth hormone; Mecasermin; Factor VIII; Factor IX; Antithrombin III; Protein C; B-Gluco-cerebrosidase; Alglucosidase- a; Laronidase; Idursulphase; Galsulphase; Agalsidase- 0; A- 1 -Proteinase inhibitor; Lactase; Lipase; Amylase; Protease; Adenosine deaminase; Human albumin; Erythropoietin; Darbepoetin- a; Filgrastim; Sargramostim; Oprelvekin; Human follicle-stimulating hormone; Human chorionic gonadotropin; Lutropin- a; Type I a -interferon; Interferon- a 2a; Interferon- a 2b; Interferon- a n3; Interferon- l a; Interferon- l b; Interferon- yl b; Aldesleukin; Alteplase; Reteplase; Tenecteplase; Urokinase; Factor VI I a; Drotrecogin- a; Salmon calcitonin; Teriparatide; Exenatide; Octreotide; Dibotermin- a; Recombinant human bone morphogenic protein 7; Histrelin; Palifermin; Becaplermin; Trypsin; Nesiritide; Botulinum toxin type A; Botulinum toxin type B; Collagenase; Human deoxy-ribonuclease I; Hyaluronidase; Papain; L-Asparaginase; Rasburicase; Lepirudin; Bivalirudin; Streptokinase; Anistreplase; Bevacizumab; Cetuximab; Panitumumab; Alemtuzumab; Rituximab; Trastuzumab; Abtacept; Anakinra; Adalimumab; Etanercept; Infliximab; Alefacept; Efalizumab; Natalizumab; Eculizumab; Antithymocyte globulin; Basiliximab; Daclizumab; Muromonab-CD3; Omalizumab; Palivizumab; Enfuvirtide; Abciximab; Pegvisomant; Crotalidae polyvalent immune Fab; Digoxin immune serum Fab; Ranibizumab; Denileukin diftitox; Ibritumomab tiuxetan; Gemtuzumab ozogamicin; Tositumomab; DNA polymerase. withdrawn
A method of functionalizing a graphene substrate, wherein the method comprises the steps of: withdrawn
The method according to claim 23, wherein the molecule is a protein, and wherein the protein is selected from a group of proteins consisting of: Insulin; Pramlintide; Growth hormone; Mecasermin; Factor VIII; Factor IX; Antithrombin III; Protein C; B-Gluco- cerebrosidase; Alglucosidase- a; Laronidase; Idursulphase; Galsulphase; Agalsidase- 0; A- 1- Proteinase inhibitor; Lactase; Lipase; Amylase; Protease; Adenosine deaminase; Human albumin; Erythropoietin; Darbepoetin- a; Filgrastim; Sargramostim; Oprelvekin; Human follicle- stimulating hormone; Human chorionic gonadotropin; Lutropin- a; Type I a-i nterferon; Attorney Docket No: Client Ref: US SN: 14/120,928 I nterferon- a 2a; I nterferon- a 2b; I nterferon- a n3; I nterferon- l a; I nterferon- l b; I nterferon- ylb; Aldesleukin; Alteplase; Reteplase; Tenecteplase; Urokinase; Factor VI I a; Drotrecogin- a; Salmon calcitonin; Teriparatide; Exenatide; Octreotide; Dibotermin- a; Recombinant human bone morphogenic protein 7; Histrelin; Palifermin; Becaplermin; Trypsin; Nesiritide; Botulinum toxin type A; Botulinum toxin type B; Collagenase; Human deoxy-ribonuclease I; Hyaluronidase; Papain; L-Asparaginase; Rasburicase; Lepirudin; Bivalirudin; Streptokinase; Anistreplase; Bevacizumab; Cetuximab; Panitumumab; Alemtuzumab; Rituximab; Trastuzumab; Abtacept; Anakinra; Adalimumab; Etanercept; Infliximab; Alefacept; Efalizumab; Natalizumab; Eculizumab; Antithymocyte globulin; Basiliximab; Daclizumab; Muromonab-CD3; Omalizumab; Palivizumab; Enfuvirtide; Abciximab; Pegvisomant; Crotalidae polyvalent immune Fab; Digoxin immune serum Fab; Ranibizumab; Denileukin diftitox; Ibritumomab tiuxetan; Gemtuzumab ozogamicin; Tositumomab; DNA polymerase. withdrawn
Layer stacks claimed or described, ordered top of device to substrate.
internally functionalized graphene substrate
Materials described outside the worked examples.
graphene substrate
nucleophilic moiety covalently linked to carbon
organic molecules (antibodies, antibody fragments, aptamers, large molecule therapeutics, oligonucleotides, oligopeptides, oligosaccharides, proteins, small molecule therapeutics)
Additional fabrication and treatment steps described in the patent.
Performance values and ranges asserted in the specification or claims.
| Property | Value | Material |
|---|---|---|
Thickness | 20–180 nm | — |
Thickness | ≤ 50 nm |
Related documents with shared materials, methods, properties, or citations.
Patent
Atlas literature
Patent
US 9,402,910Patent drawings and their descriptions. Click a drawing to enlarge it.
FIG. 1 is an illustration of a graphene substrate (100) having non-edge regions (110) and edge regions (120).
FIG. 2 is an illustration of a graphene substrate (200) having holes (210) where there is no graphene, edge regions (220) and non-edge regions (230).
FIG. 3 is an illustration of a portion of a graphene substrate (300) having non-edge regions (310) and epoxy groups (320) within the non-edge regions.
FIG. 4 is an illustration of a portion of a graphene substrate (400) having non-edge regions (410) and hydroxyl groups (420) within the non-edge regions.
FIG. 5 is an illustration of a graphene substrate (500) having non-edge regions (510) and edge regions (520), and where the non-edge regions are functionalized …
FIG. 6 is an illustration of a graphene substrate (600) having edge regions (620) and non- edge regions (630), as well as holes (610) where there is no …
FIG. 7 is an illustration of three ribbons (700) of graphene substrates that have edge regions (710), non-edge regions (720), and where the non-edge regions …
FIG. 8 is an illustration of system (800) of interconnected graphene substrates (810), where the graphene substrates have edge regions (830) and non-edge …
FIG. 9 is an illustration of the functionalization of epoxy groups (920) on non-edge regions (910) of a portion of a graphene substrate (900) through reaction …
FIG. 10 is an illustration of the functionalization of hydroxyl groups (1020) on non-edge regions (1010) of a portion of a graphene substrate (1000) through …
FIG. 11 is an illustration of a portion of a graphene substrate (1100) functionalized on a non-edge region (1110) with an amine including a pyrene moiety …
FIG. 12 is an illustration of a portion of a graphene substrate (1200) f u nctionalized on a non- edge region (1210) with an amine including an ammonium ion …
FIG. 13 is an illustration of a portion of a graphene substrate (1300) functionalized on a non-edge region (1310) with an amine including a biotin moiety …
FIG. 14 is an illustration of a portion of a graphene substrate (1400) functionalized on a non-edge region (1410) with an amine including a thiol moiety (1440) …
FIG. 15 is an illustration of a portion of a graphene substrate (1500) functionalized on a non-edge region (1510) with an amine including an amino triacetic …
FIG. 16 is an illustration of a portion of a graphene substrate (1600) functionalized on a non-edge region (1610) with an amine including an amino triacetic …
FIG. 17 is an illustration of a portion of a graphene substrate (1700) functionalized on a non-edge region (1710) through non-covalent association of a …
FIG. 18 is an illustration of a portion of a graphene substrate (1800) functionalized on a non-edge region (1810) through non-covalent association of an …
FIG. 19 is an illustration of a portion of a graphene substrate (1900) functionalized on a non-edge region (1910) through non-covalent association of a …
FIG. 20 is an illustration of a portion of a graphene substrate (2000) functionalized on a non-edge region (2010) through non-covalent association of a …
FIG. 21 is an illustration of a molecule (2140) bound to a graphene substrate (2100) through a bond (2110) where a binding site (2150) on the molecule is …
FIG. 22 is an illustration of a side view of a graphene substrate (2200) adhered to a supporting substrate (2210).
Claims define the patent's legal scope. Independent claims stand alone; dependent claims (nested) narrow them. Click a claim to expand its dependents.
A graphene substrate, wherein the substrate comprises edge and non-edge regions, and wherein organic or inorganic molecules are bound to a nucleophilic moiety covalently linked to a carbon molecule in the non-edge regions of the substrate, and wherein the organic or inorganic molecules are present on the non-edge regions at a population greater than about one molecule per 30,000 nm 2
The graphene substrate according to claim 1, wherein organic molecules are present on the substrate, and wherein the organic molecules are selected from a group consisting of: antibodies; antibody fragments; aptamers; large molecule therapeutics; oligonucleotides; oligopeptides; oligosaccharides, proteins and small molecule therapeutics.
A method of functionalizing a graphene substrate, wherein the method comprises the steps of: a) obtaining a graphene substrate that has edge regions and non-edge regions, wherein the nonedge regions comprise epoxy moieties; b) reacting the epoxy moieties with a Nu-M, wherein Nu is a nucleophilic moiety and M is an attached organic or inorganic moiety, thereby functionalizing the graphene substrate. withdrawn
The method according to claim 14, wherein Nu is NH 2, and wherein M is an attached organic moiety, and wherein the organic moiety is selected from a group of organic moieties consisting of: an antibody; a linking group attached to an antibody; an antibody fragment; a linking group attached to an antibody fragment; a linking group attached to an aptamer; a protein; a linking group attached to a protein; an oligopeptide; a linking group attached to an oligopeptide; a linking group attached to an oligosaccharide; a large molecule therapeutic; a linking group attached to a large molecule therapeutic; a small molecule therapeutic; a linking group attached to a small molecule therapeutic. withdrawn
A method of functionalizing a graphene substrate, wherein the method comprises the steps of. a) obtaining a graphene substrate that has edge regions and non-edge regions, wherein the nonedge regions comprise hydroxy moieties; Attorney Docket No: Client Ref: US SN: 14/120,928 b) reacting the hydroxyl moieties with a E-M, wherein E is an electrophilic moiety and M is an attached organic or inorganic moiety, thereby functionalizing the graphene substrate. withdrawn
The method according to claim 19, wherein EM is OCN-Protein, wherein the N atom is part of the protein, and wherein the protein is selected from a group of proteins consisting of. Insulin; Pramlintide; Growth hormone; Mecasermin; Factor VIII; Factor IX; Antithrombin III; Protein C; B-Gluco-cerebrosidase; Alglucosidase- a; Laronidase; Idursulphase; Galsulphase; Agalsidase- 0; A- 1 -Proteinase inhibitor; Lactase; Lipase; Amylase; Protease; Adenosine deaminase; Human albumin; Erythropoietin; Darbepoetin- a; Filgrastim; Sargramostim; Oprelvekin; Human follicle-stimulating hormone; Human chorionic gonadotropin; Lutropin- a; Type I a -interferon; Interferon- a 2a; Interferon- a 2b; Interferon- a n3; Interferon- l a; Interferon- l b; Interferon- yl b; Aldesleukin; Alteplase; Reteplase; Tenecteplase; Urokinase; Factor VI I a; Drotrecogin- a; Salmon calcitonin; Teriparatide; Exenatide; Octreotide; Dibotermin- a; Recombinant human bone morphogenic protein 7; Histrelin; Palifermin; Becaplermin; Trypsin; Nesiritide; Botulinum toxin type A; Botulinum toxin type B; Collagenase; Human deoxy-ribonuclease I; Hyaluronidase; Papain; L-Asparaginase; Rasburicase; Lepirudin; Bivalirudin; Streptokinase; Anistreplase; Bevacizumab; Cetuximab; Panitumumab; Alemtuzumab; Rituximab; Trastuzumab; Abtacept; Anakinra; Adalimumab; Etanercept; Infliximab; Alefacept; Efalizumab; Natalizumab; Eculizumab; Antithymocyte globulin; Basiliximab; Daclizumab; Muromonab-CD3; Omalizumab; Palivizumab; Enfuvirtide; Abciximab; Pegvisomant; Crotalidae polyvalent immune Fab; Digoxin immune serum Fab; Ranibizumab; Denileukin diftitox; Ibritumomab tiuxetan; Gemtuzumab ozogamicin; Tositumomab; DNA polymerase. withdrawn
A method of functionalizing a graphene substrate, wherein the method comprises the steps of: withdrawn
The method according to claim 23, wherein the molecule is a protein, and wherein the protein is selected from a group of proteins consisting of: Insulin; Pramlintide; Growth hormone; Mecasermin; Factor VIII; Factor IX; Antithrombin III; Protein C; B-Gluco- cerebrosidase; Alglucosidase- a; Laronidase; Idursulphase; Galsulphase; Agalsidase- 0; A- 1- Proteinase inhibitor; Lactase; Lipase; Amylase; Protease; Adenosine deaminase; Human albumin; Erythropoietin; Darbepoetin- a; Filgrastim; Sargramostim; Oprelvekin; Human follicle- stimulating hormone; Human chorionic gonadotropin; Lutropin- a; Type I a-i nterferon; Attorney Docket No: Client Ref: US SN: 14/120,928 I nterferon- a 2a; I nterferon- a 2b; I nterferon- a n3; I nterferon- l a; I nterferon- l b; I nterferon- ylb; Aldesleukin; Alteplase; Reteplase; Tenecteplase; Urokinase; Factor VI I a; Drotrecogin- a; Salmon calcitonin; Teriparatide; Exenatide; Octreotide; Dibotermin- a; Recombinant human bone morphogenic protein 7; Histrelin; Palifermin; Becaplermin; Trypsin; Nesiritide; Botulinum toxin type A; Botulinum toxin type B; Collagenase; Human deoxy-ribonuclease I; Hyaluronidase; Papain; L-Asparaginase; Rasburicase; Lepirudin; Bivalirudin; Streptokinase; Anistreplase; Bevacizumab; Cetuximab; Panitumumab; Alemtuzumab; Rituximab; Trastuzumab; Abtacept; Anakinra; Adalimumab; Etanercept; Infliximab; Alefacept; Efalizumab; Natalizumab; Eculizumab; Antithymocyte globulin; Basiliximab; Daclizumab; Muromonab-CD3; Omalizumab; Palivizumab; Enfuvirtide; Abciximab; Pegvisomant; Crotalidae polyvalent immune Fab; Digoxin immune serum Fab; Ranibizumab; Denileukin diftitox; Ibritumomab tiuxetan; Gemtuzumab ozogamicin; Tositumomab; DNA polymerase. withdrawn
Layer stacks claimed or described, ordered top of device to substrate.
internally functionalized graphene substrate
Materials described outside the worked examples.
graphene substrate
nucleophilic moiety covalently linked to carbon
organic molecules (antibodies, antibody fragments, aptamers, large molecule therapeutics, oligonucleotides, oligopeptides, oligosaccharides, proteins, small molecule therapeutics)
Additional fabrication and treatment steps described in the patent.
Performance values and ranges asserted in the specification or claims.
| Property | Value | Material |
|---|---|---|
Thickness | 20–180 nm | — |
Thickness | ≤ 50 nm |
Related documents with shared materials, methods, properties, or citations.
proteins (therapeutic proteins)
large molecule therapeutics
oligonucleotides
oligopeptides
oligosaccharides
small molecule therapeutics
epoxy moieties on graphene non-edge regions
hydroxy moieties on graphene non-edge regions
| — |
Thickness | ≤ 1 nM | — |
Thickness | ≥ 500 nm | — |
GRAPHENE DERIVATIVES, TRANSPARENT CONDUCTIVE FILMS, ORGANIC ELECTROLUMINESCENT DEVICES, METHODS OF PREPARING THE GRAPHENE DERIVATIVES AND METHODS OF PREPARING ANODE LAYERS OF THE DEVICES
proteins (therapeutic proteins)
large molecule therapeutics
oligonucleotides
oligopeptides
oligosaccharides
small molecule therapeutics
epoxy moieties on graphene non-edge regions
hydroxy moieties on graphene non-edge regions
| — |
Thickness | ≤ 1 nM | — |
Thickness | ≥ 500 nm | — |
GRAPHENE DERIVATIVES, TRANSPARENT CONDUCTIVE FILMS, ORGANIC ELECTROLUMINESCENT DEVICES, METHODS OF PREPARING THE GRAPHENE DERIVATIVES AND METHODS OF PREPARING ANODE LAYERS OF THE DEVICES
proteins (therapeutic proteins)
large molecule therapeutics
oligonucleotides
oligopeptides
oligosaccharides
small molecule therapeutics
epoxy moieties on graphene non-edge regions
hydroxy moieties on graphene non-edge regions
| — |
Thickness | ≤ 1 nM | — |
Thickness | ≥ 500 nm | — |
GRAPHENE DERIVATIVES, TRANSPARENT CONDUCTIVE FILMS, ORGANIC ELECTROLUMINESCENT DEVICES, METHODS OF PREPARING THE GRAPHENE DERIVATIVES AND METHODS OF PREPARING ANODE LAYERS OF THE DEVICES
proteins (therapeutic proteins)
large molecule therapeutics
oligonucleotides
oligopeptides
oligosaccharides
small molecule therapeutics
epoxy moieties on graphene non-edge regions
hydroxy moieties on graphene non-edge regions
| — |
Thickness | ≤ 1 nM | — |
Thickness | ≥ 500 nm | — |
GRAPHENE DERIVATIVES, TRANSPARENT CONDUCTIVE FILMS, ORGANIC ELECTROLUMINESCENT DEVICES, METHODS OF PREPARING THE GRAPHENE DERIVATIVES AND METHODS OF PREPARING ANODE LAYERS OF THE DEVICES